⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15326932 | 0.83 | — | — | |
| SCHEMBL3839495 | 0.81 | — | — | |
| SCHEMBL24397612 | 0.74 | — | — | |
| SCHEMBL15046729 | 0.74 | — | — | |
| SCHEMBL14791326 | 0.69 | SHBG (0.33) | — | |
| SCHEMBL12229587 | 0.69 | — | — | |
| SCHEMBL6458899 | 0.69 | SHBG (0.33) | — | |
| SCHEMBL6458908 | 0.69 | SHBG (0.33) | — | |
| SCHEMBL11442767 | 0.67 | SHBG (0.33) | — | |
| SCHEMBL11442768 | 0.67 | SHBG (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110156738-B | Total synthesis method of illitane type sesquiterpene reaction intermediate and natural product | 中北大学 | 2023-01-03 | — | — | CN | disclosed |
| WO-2021180107-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-09-16 | — | — | WO | disclosed |
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190152947-A1 | PIPERIDINES AS MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-23 | — | — | US | disclosed |
| EP-3184526-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2343299-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2343299-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2474545-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2455382-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2426129-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| CN-101160125-A | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO INC (US) | 2008-04-09 | — | — | CN | disclosed |
| EP-1874301-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007106317-A2 | PHARMACEUTICAL COMBINATIONS OF HCV-PROTEASE AND -IRES INHIBITORS | SCHERING CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130626-A2 | METHOD FOR MODULATING ACTIVITY OF HCV PROTEASE THROUGH USE OF A NOVEL HCV PROTEASE INHIBITOR TO REDUCE DURATION OF TREATMENT PERIOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006113150-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2005058821-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3/NS4A SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-06-30 | — | — | WO | disclosed |